| Literature DB >> 35436071 |
Andrei George Iosifescu1,2, Alexandru Popescu2, Toma Andrei Iosifescu3, Alina Teodora Timişescu2, Sorin Maximeasa2, Vlad Anton Iliescu1,2.
Abstract
INTRODUCTION: Functional tricuspid regurgitation (TR) is known to complicate adult atrial septal defect (ASD), but its management is still under debate. We reviewed our experience in ASD surgery, focusing on associated functional TR and its treatment.Entities:
Keywords: Adult; Atrial Heart Septal Defects; Cardiac Surgical Procedures; Decision Making; Tricuspid Valve Insufficiency
Mesh:
Year: 2022 PMID: 35436071 PMCID: PMC9162427 DOI: 10.21470/1678-9741-2020-0503
Source DB: PubMed Journal: Braz J Cardiovasc Surg ISSN: 0102-7638
General clinical data.
| Number of patients | 206 |
|---|---|
| Age (years) | 40.3±13 |
| Female:Male | 138:68 (≈2) |
| PAPVC | 41 (19.9%) |
| NYHA heart failure class | |
| I | 10 (4.9%) |
| II | 147 (71.4%) |
| III | 47 (22.8%) |
| IV | 2 (0.9%) |
| Preoperative AF | 32 (15.5%) |
| ASD diameter (mm) | 24.2±8.1 |
| Preoperative TR grade (0-4) | 2±1 |
| TR surgery | 66 (32%) |
| Other associated operations: | |
| CABG | 6 (≈3%) |
| Treatment of pulmonary artery aneurysm | 2 (≈1%) |
| Preoperative RVEDD (mm) | 46.1±7.7 |
| Preoperative TAD (mm) | 38.9±5.1 |
| Preoperative LVEF (mm) | 57.4±6.2 |
| Preoperative PASP (mmHg) | 44.3±11 |
| Preoperative Qp/Qs | 2.55±0.8 |
| Postoperative RVEDD (mm) | 39.1±7 |
| ΔRVEDD | 7.6±5.9 |
| Postoperative TR grade (0-4) | 0.85±0.7 |
| ΔTR | 1.22±1 |
| Complications | 37 (18%) |
| Death | 1 (0.49%) |
| Hospital stay (days) | 8.8 ±3.3 |
Comparison of tricuspid regurgitation (TR) class defined subgroups.
| TR < 2 (No/mild) | TR = 2 (Moderate) | TR > 2 (> Moderate) | ||
|---|---|---|---|---|
| Number (%) | 72 (≈35%) | 62 (≈30%) | 72 (≈35%) | |
| Age (years) | 35.7±12.6 | 39.5±11.7 | 45.6±12.4 | |
| Female:Male | 53:19 (≈2.8) | 38:24 (≈1.6) | 47:25 (≈1.8) | NS |
| PAPVC | 13 (18.1%) | 11 (17.7%) | 17 (23.6%) | NS |
| NYHA heart failure class ≥ III | 11 (15.3%) | 10 (16.1%) | 28 (38.9%) | |
| Preoperative AF | 9 (12.5%) | 9 (14.5%) | 14 (19.4%) | NS |
| ASD diameter (mm) | 22.4±6.8 | 25.4±8.5 | 25±8.6 | |
| Preoperative TR grade (0-4) | 0.93±0.48 | 2 | 3.05±0.45 | |
| TR surgery | 0 | 12 (16.7%) | 54 (75%) | |
| Preoperative RVEDD (mm) | 42.8±6.8 | 46.4±7.7 | 49.2±7.3 | |
| Preoperative TAD (mm) | 36.1±.4.8 | 38.7±4.6 | 41.9±4.1 | |
| Preoperative LVEF (mm) | 59.7±6.4 | 56.7±5.9 | 55.7±5.4 | |
| Preoperative PASP (mmHg) | 40.5±10.6 | 43.8±10.8 | 57.5±10.4 | |
| Preoperative Qp/Qs | 2.4±0.9 | 2.7±0.6 | 2.6±0.6 | NS |
| Postoperative RVEDD (mm) | 36.3±5.5 | 39.5±7.5 | 41±7 | |
| ΔRVEDD | 6.9±6.2 | 7.3±5.9 | 8.5±5.7 | NS |
| Postoperative TR grade (0-4) | 0.53±0.5 | 1.10 ±0.68 | 0.98±0.81 | |
| ΔTR | 0.48±0.45 | 0.92±0.68 | 2.06±0.95 | <1.15 E-25 |
| Complications | 12 (16.7%) | 10 (16.3%) | 15 (20.8%) | NS |
| Death | 0 | 0 | 1 (1.38%) | NS |
| Hospital stay (days) | 8.5±3.5 | 8.8±2.4 | 9.1±3.6 | NS |
Patients with tricuspid regurgitation (TR) ≥ 2: shunt closure only group vs. additional tricuspid valve surgery group.
| Shunt closure only (n=68) | Tricuspid valve surgery (n=66) | ||
|---|---|---|---|
| Age (years) | 40.1±11.5 | 45.5±12.9 | 0.011 |
| Sex (Female:Male) | 44:24:00 | 41:25:00 | NS |
| PAPVC | 12 (17.6%) | 16 (24.2%) | NS |
| NYHA heart failure class ≥ III | 13 (19.1%) | 25 (37.8%) | |
| Preoperative AF (active/history) | 11 (16.2%) | 12 (18.2%) | NS |
| ASD diameter (mm) | 24.2±8 | 26.2±9 | NS |
| Preoperative TR grade (0-4) | 2.22±0.4 | 2.92±0.6 | 4.5E-12 |
| Preoperative RVEDD (mm) | 45.6±6.1 | 50.2±8.3 | |
| Preoperative TAD (mm) | 37.3±4.5 | 42.2±4.7 | 1.5E-10 |
| Preoperative LVEF (mm) | 56.7±6 | 55.6±5.3 | NS |
| Preoperative PASP (mmHg) | 44.9±11 | 46.8±10.4 | NS |
| Preoperative Qp/Qs | 2.6±0.6 | 2.7±0.7 | NS |
| Postoperative RVEDD (mm) | 38.5±5 | 42.3 ±8.3 | |
| ΔRVEDD | 7.1±5.8 | 8.8±5.7 | NS |
| Postoperative TR grade (0-4) | 1.42±0.6 | 0.62±0.68 | 5.7E-11 |
| ΔTR | 0.8±0.55 | 2.3±0.77 | 6.8E-24 |
| %ΔTR | 36±26% | 79±23% | |
| Complications | 12 (17.6%) | 13 (19.7%) | NS |
| Death | 0 | 1 (1.5%) | NS |
| Hospital stay (days) | 8.7±2.5 | 9.2±3.7 | NS |
Nominal and percentage tricuspid regurgitation (TR) decrease after shunt closure, with and without tricuspid valve (TV) surgery, in different classes of TR.
| Preoperative TR | TV surgery | N | Preoperative TR | Postoperative TR | ∆TR | %∆TR |
|---|---|---|---|---|---|---|
| 0 < TR < 2 | No | 59 | 1.14±0.2 | 0.65±0.47 | 0.48±0.45 | 43±42% |
| TR = 2 | No | 50 | 2 | 1.28±0.6 | 0.72±0.6 | 36±28.8% |
| Yes | 12 | 2 | 0.25±0.38 | 1.75±0.4 | 87.5±18% | |
| TR > 2 | No | 18 | 2.83±0.24 | 1.81±0.48 | 1.03±0.4 | 36.7±14% |
| Yes | 54 | 3.12±0.48 | 0.7±0.7 | 2.42±0.8 | 77.4±23% |
Comparison of subgroups defined by atrial septal defect (ASD) device closure availability in our institution.
| 2005-2015 | 2016-2019 | ||
|---|---|---|---|
| ASD device closure available in hospital | No | Yes | |
| Number of patients | 165 | 41 | |
| Cases/year | 15±4.3 | 10.3±1.8 | |
| Age (years) | 39±12.2 | 45.5±14.5 | |
| PAPVC | 33 (20%) | 8 (19.5%) | NS |
| ASD diameter | 23.2±7.4 | 28.4±9.2 | |
| Preoperative NYHA heart failure class ≥ III | 33 (20%) | 10 (24.3%) | NS |
| Atrial fibrillation | 25 (15.2%) | 7 (17.1%) | NS |
| Preoperative TR grade | 1.9±0.9 | 2.4±1.1 | |
| Preoperative TAD | 38.2±4.9 | 41.7±5.1 | |
| Preoperative RVEDD | 45.1±7.1 | 50.1±8.4 | |
| Preoperative PASP | 44.6±10.8 | 42.9±11.5 | NS |
| LVEF | 58.1±6.3 | 54.6±4.6 | |
| Qp/Qs | 2.5±0.7 | 2.78±0.9 | NS |
| Preoperative TR > 2 | 51 (30.9%) | 21 (51.2%) | |
| Patients with TV surgery: n (%) | 41 (24.8%) | 25 (61%) | |
| Postoperative TR grade | 0.87±0.74 | 0.80±0.60 | NS |
| Associated surgery (CABG, PA aneurysm) | 2 | 6 | |
| Complicated cases: n (%) | 27 (16.4%) | 10 (24.4%) | NS |
| In-hospital death | 1 | 0 | NS |
| Hospital stay (days) | 8.6±2.3 | 9.6±5.7 | NS |
Abbreviations, Acronyms & Symbols
| %ΔTR | = Percentage of TR decrease | PAPVC | = Partial anomalous pulmonary venous connection |
| ΔRVEDD | = RVEDD variation | PASP | = Pulmonary artery systolic pressure |
| ΔTR | = TR variation | Qp/Qs | = Ratio between pulmonary and systemic output |
| AF | = Atrial fibrillation | RV | = Right ventricular |
| ANOVA | = Analysis of variance | RVEDD | = Right ventricular end-diastolic diameter |
| ASD | = Atrial septal defect | TAD | = Tricuspid annulus diameter |
| CAGB | = Coronary artery bypass grafting | TR | = Tricuspid regurgitation |
| LVEF | = Left ventricular ejection fraction | TV | = Tricuspid valve |
| NYHA | = New York Heart Association | TVR | = Tricuspid valve repair |
| PA | = Pulmonary artery |
Authors’ Roles & Responsibilities
| AGI | Substantial contributions to the conception and design of the work; and the acquisition, analysis and interpretation of data for the work; drafting the work and revising it critically for important intellectual content; final approval of the version to be published |
| AP | Substantial contributions to the acquisition, analysis and interpretation of data for the work; drafting the work and revising it; final approval of the version to be published |
| TAI | Substantial contributions to the acquisition, analysis and interpretation of data for the work; drafting the work and revising it; final approval of the version to be published |
| ATT | Substantial contributions to the acquisition, analysis and interpretation of data for the work; drafting the work and revising it; final approval of the version to be published |
| SM | Substantial contributions to the conception of the work; drafting the work and revising it critically; final approval of the version to be published |
| VAI | Substantial contributions to the conception and design of the work; revising it critically for important intellectual content; final approval of the version to be published |